-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20, the Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment (RDPAC) held the RDPAC 2021 National Tumor Prevention and Control Promotion Week and the launch of the report "Joining Innovative Medicine Industry to Help Build a Healthy China".
This meeting was hosted by Kang Wei, Executive President of RDPAC, and Shao Ming, Deputy Secretary-General of the Science Committee of the Chinese Anti-Cancer Association, Gu Jin, Chief Physician of Colorectal Tumor Surgery, Peking University Cancer Hospital, Dean of Peking University Shougang Hospital, and No.
RDPAC CEO Conway said in his opening remarks: "At present, the overall five-year survival rate of cancer patients in China is 40%, which is 10% higher than that of 10 years ago.
Cancer has become one of the main causes of morbidity and death in the global population.
Yuan Zhun, Director of RDPAC Market Access, gave a comprehensive interpretation of the RDPAC report.
Shao Ming, deputy secretary-general of the Science Popularization Committee of the Chinese Anti-Cancer Association, shared the theme of "The Power of Popularization of Science" at the press conference.
Early screening, early diagnosis and treatment, rationalized medication, breakthrough methods, and Sino-foreign cooperation light up the road to cancer
Early screening, early diagnosis and treatment, rationalized medication, breakthrough methods, and Sino-foreign cooperation light up the road to cancerIn the round-table discussion session of the conference, the guests discussed how to raise the public's awareness of cancer protection for early detection, early diagnosis, and early treatment, and the availability of innovative anti-cancer drugs, so as to reduce the burden of cancer patients' treatment and society.
Picture: The guest discussion site, from left to right
Conway, CEO of RDPAC
Gu Jin, Chief Physician of Colorectal Tumor Surgery, Peking University Cancer Hospital and Dean of Peking University Shougang Hospital
Hu Yunfu, Chief Medical Officer of Genetron Health
Pharmacist Zhai Suodi, Director of Pharmacy Department of Peking University Third Hospital
Li Lilly China Senior Vice President and Head of the Center for Drug Development and Medical Affairs Wang Li
Yang Ying, Head of Global Strategy and Business Development Asia, Pfizer
Dr.
At the end of December last year, the National Health Commission issued the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)" to provide standardized guidance on the clinical use of anti-cancer drugs and to further rationalize the use of drugs in the industry.
Gu Jin, Dean of Shougang Hospital, said: “Cancer has become a chronic disease.
Wang Li, senior vice president of Eli Lilly China and head of the Center for Drug Development and Medical Affairs, emphasized from the perspective of innovative research and development: "In recent years, multinational pharmaceutical companies have worked closely with international research institutions and experts in various fields in China to carry out diversified drug R&D innovations.
In today's globalization, drug innovation is inseparable from the strong cooperation of multinational and local companies.
The RDPAC report shows that in 2040, China can reduce the overall disease burden by up to 55% and extend the healthy life span of the whole people through the three major health improvement measures of "pre-treatment", "pre-treatment" and "pre-treatment".
